Pleuritis Induced by Brigatinib During the Treatment of Non‐Small Cell Lung Cancer
Shohei Yano, Moon Hee Hwang, Tomoko Harima, Shota Takahashi, Takumi Yamada, Nao Yoshida, Yuki Yoshida, Atsushi Hirai · 2026
Read Pleuritis Induced by Brigatinib During the Treatment of Non‐Small Cell Lung Cancer by Shohei Yano, Moon Hee Hwang, Tomoko Harima, Shota Takahashi, Takumi Yamada, Nao Yoshida, Yuki Yoshida, Atsushi Hirai (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13138867.txt.
Description
Shohei Yano and co-authors report a 2026 case of lung inflammation of the pleura linked to the cancer drug brigatinib. Their patient, a woman in her late seventies with a gene marked type of lung cancer, began the drug as a third line of care. Soon after, she developed breathlessness, fever, raised inflammation markers, and fluid on both sides of the chest.
Fluid tests showed an immune rich fluid with no sign of cancer or infection, pointing to the drug as the cause. Stopping brigatinib brought fast clinical and scan based improvement, and the pleuritis did not return even as the cancer later grew. Restarting the drug at a low dose shrank the tumor without bringing the pleuritis back, and a higher dose was also borne well. The authors flag drug caused pleuritis as a cause to weigh when fluid appears on this therapy.
Catalog record
| CREATOR | Shohei Yano, Moon Hee Hwang, Tomoko Harima, Shota Takahashi, Takumi Yamada, Nao Yoshida, Yuki Yoshida, Atsushi Hirai |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 9 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |